Lubiprostone has gained widened FDA approval, making it the first oral therapy approved for opioid-linked constipation in adults who have chronic, noncancer pain. The drug was previously approved for chronic idiopathic constipation among adults and constipation associated with irritable bowel syndrome in adult women.
A Phase III study of lubiprostone showed it was safe for patients with irritable bowel syndrome and constipation who took it twice daily for 36 weeks. Marketed as Amitiza by Sucampo Pharmaceuticals and Takeda Pharmaceutical, the drug is indicated for chronic idiopathic constipation and IBS-C, which often require long-term treatment.
Patients who took a combination pill of ibuprofen plus the acid reflux drug famotidine developed fewer gastric or duodenal ulcers than those who just got the nonsteroidal anti-inflammatory medication, Yale University researchers reported. The study in the American Journal of Gastroenterology included 1,533 patients who needed NSAID therapy for six months or more. Researchers said using just one pill could increase treatment compliance.
Halina Kwiatkowska, owner of Parsley Sage & Thyme Health Store, says more people recognize celiac disease as an autoimmune condition with symptoms beyond digestive ailments. She says completing the switch to a gluten-free diet can take three months, with many people falling off the plan about halfway through only to find their symptoms return.